Sutro Biopharma is a clinical-stage drug discovery, development and manufacturing company creating next-generation protein therapeutics for oncology and autoimmune disorders using proprietary integrated cell-free protein synthesis and site-specific conjugation platforms, XpressCF™ and XpressCF+™. Its pipeline includes cytokine-based immuno-oncology therapeutics, antibody drug conjugates (ADCs), and bispecific antibodies directed mainly at clinically validated targets. The company has two internally developed ADCs highlighted in the articles: STRO-001, in Phase 1 testing for lymphoma and multiple myeloma, and STRO-002, expected to enter clinical trials for ovarian and endometrial cancer by early 2019. Sutro also collaborates with select pharmaceutical and biotech companies to discover and develop novel therapeutics. The company plans to use recent financing to advance its oncology pipeline, further early-stage programs, and continue platform technology advancement. Sutro is led by CEO Bill Newell and is based in South San Francisco, CA. Sutro Biopharma develops new protein therapeutics using its cell-free protein synthesis technology to create antibody drug conjugates and bispecific antibodies. The company has established a cGMP facility for production of clinical supplies. It has formed partnerships with biopharma companies, including a collaboration with Celgene to design and develop novel ADCs and bispecific antibodies and to manufacture a proprietary Celgene antibody. Led by CEO William J. Newell, Sutro intends to use the funds to expand its proprietary immuno-oncology product pipeline. Founded in 2003 and based in South San Francisco, the company has raised over $90M since its founding. It secured a $26M Series D to support pipeline and manufacturing expansion. Sutro Biopharma is a San Francisco-based company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies. The company has developed biochemical synthesis technology that allows rapid and systematic exploration of many protein drug variants to identify drug candidates. Sutro develops its own drug pipeline and collaborates with select pharmaceutical and biotech companies in the discovery and development of novel protein therapeutics. Led by CEO William Newell, the company closed a $16.5M second tranche of its Series C financing. The financing was announced on 09/05/2012. Sutro Biopharma develops and designs novel protein therapeutics and biosuperiors with site-directed modifications, including incorporation of non-natural amino acids. The company operates a biochemical protein synthesis platform used to create site-directed modified proteins. Sutro intends to use the new capital to further advance its biotherapeutics and to bring its protein synthesis platform to current Good Manufacturing Practice (cGMP) standards. It secured $36.5m in a Series C financing that consists of two tranches, with the first $20m tranche closed on Nov. 5. To date the company has raised a total of $59.5m in financing. In conjunction with the financing Dr. Chen and Armen Shanafelt, Ph.D. joined Sutro’s board of directors.

Total raised

$164M

Funding rounds

4

Latest round

Series E

Latest activity

Jul 2018